Bausch + Lomb Corporation (BLCO) on Thursday reported topline Phase 2 results for its topical eye drop BL1332, and the headline is that it missed its primary pain-reduction endpoint after photorefractive keratectomy (PRK) surgery.
PRK, for the uninitiated, is a flapless laser eye surgery that reshapes the cornea to correct myopia (nearsightedness), hyperopia (farsightedness), and astigmatism. It is not a gentle procedure, and the recovery can be unpleasant.
The data showed the drug delivered consistent directional relief and favorable safety. No approved therapies currently target the underlying neurosensory pathways causing debilitating ocular surface pain after surgery or ocular disorders.
Bausch + Lomb designed BL1332 as a first-in-class topical TRPV1 antagonist to block a key ocular pain receptor rather than merely treating symptoms.
Phase 2 Study Design And Efficacy Results
The randomized, double-masked, vehicle-controlled trial enrolled 129 adults undergoing unilateral sequential PRK surgery for myopia.
Researchers randomized participants to BL1332 0.30%, BL1332 0.15%, or vehicle immediately post-surgery, administering five doses over 24 hours while awake for three days, with follow-up through Day 14.
The study missed its primary endpoint of showing a statistically significant improvement versus vehicle in sum of pain intensity differences (SPID) over 24 hours.
BL1332 0.30% recorded a least-squares mean difference of -11.5 against vehicle, while 0.15% recorded -9.0, with negative values favoring BL1332.
Both doses produced numerically greater pain relief than vehicle across every SPID measurement through 72 hours, and the 0.30% dose delivered a nominally significant reduction during the first six hours.
Corneal Healing And Safety Profile
Between six and 12 hours post-surgery, higher proportions of BL1332 patients reported complete pain relief versus vehicle. At six hours, 14.0% of patients on 0.30% and 14.6% on 0.15% reported complete relief, compared with 3.7% on vehicle.
An anterior segment OCT subset showed greater central corneal epithelial thickness at Day 3 for both BL1332 doses, suggesting faster corneal surface healing.
Patients tolerated BL1332 well, experiencing treatment-emergent adverse events at rates of 6.0% for 0.30%, 13.7% for 0.15%, and 14.8% for vehicle.
The trial recorded zero treatment-related adverse events, serious adverse events, or discontinuations, identifying no new safety signals.
FDA Discussions And Next Steps
Bausch + Lomb is completing its dataset analysis and plans to review these findings alongside prior Phase 1b capsaicin-induced pain data with the U.S. Food and Drug Administration to guide future trial designs and endpoints.
BLCO Price Action: Bausch & Lomb shares were down 2.27% at $20.22 at the time of publication on Friday, according to market data.